---
document_datetime: 2024-11-27 14:02:34
document_pages: 54
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/copalia-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: copalia-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 98.8955581
conversion_datetime: 2025-12-20 17:49:46.18361
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Copalia

Proceduralstepstakenandscientificinformationaftertheauthorisation

| Application number   | Scope                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued2 / amended on   | Product Information affected3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|-----------|
| IG/1804              | B.II.b.2.c.1 - Change to importer, batch release arrangements andquality controltestingof theFP- Replacementoradditionofamanufacturer responsibleforimportation and/orbatchrelease- Not includingbatch control/testing | 21/11/2024                          |                                            | Annex II and PL                 |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3 SmPC (Summary of Product Characteristics), Annex I, Labelling, PL (Package Leaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g. summary of product characteristics, annexII, labelling,package leaflet).The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a)of Regulation(Eu)No.712/2012, or within one year for other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | B.Ill.1.a.2-Submissionofanew/updatedor deletion of Ph. Eur. Certificate of Suitability to the relevant Ph.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                        | 28/08/2024   | n/a   |             | IG/1784   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------|-----------|
| IG/1763 | A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                  | 04/07/2024   | n/a   |             |           |
| IG/1708 | B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificateof Suitability to the relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                         | 08/04/2024   | n/a   |             |           |
|         | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                          | 25/01/2024   |       | SmPC and PL | WS/2610   |
|         | This was an applicationfor a group of variations. A.4-Administrativechange-Changeinthename and/oraddressofamanufactureroranASMFholder or supplier of the AS, starting material, reagent or intermediateused in themanufactureof theASor manufacturerofanovelexcipient A.4-Administrative change-Changein thename and/or address of a manufacturer or an ASMF holder orsupplieroftheAS，startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturerofanovelexcipient | 14/09/2023   | n/a   |             | IG/1666/G |

<div style=\"page-break-after: always\"></div>

| IG/1644/G   | This was an application for a group of variations. A.7-Administrativechange-Deletionof manufacturing sites A.7-Administrativechange-Deletionof manufacturingsites                                                                                                                                                                                                                                                          | 08/08/2023   | n/a   |                                                                                                                                                                                                                                                                                                     |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1637     | B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                            | 19/07/2023   | n/a   |                                                                                                                                                                                                                                                                                                     |
|             | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.3.a-Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a-Change in the manufacturing process of the finished or intermediate product - Minor change inthemanufacturingprocess | 02/03/2023   | n/a   | WS/2363/G B.II.b.3.a-Change in the manufacturing process of the finished or intermediate product - Minor change inthemanufacturingprocess B.II.b.4.a -Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | in the manufacturing process B.II.b.4.a -Change in the batch size (including batch sizeranges)of the finishedproduct-Up to10-fold comparedtotheoriginallyapprovedbatchsize B.II.b.4.a-Change in the batch size(includingbatch size ranges) of the finished product -Up to 10-fold comparedtotheoriginallyapprovedbatchsize                                                                                                    |            |            |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1598/G | Thiswas an applicationfor a group of variations. A.7-Administrative change-Deletion of manufacturingsites A.7-Administrativechange-Deletionof manufacturing sites A.7-Administrativechange-Deletionof manufacturing sites A.7-Administrative change-Deletion of manufacturing sites                                                                                                                                           | 28/02/2023 | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| WS/2337/G | This was an application for a group of variations following a worksharing procedure according to Article 20of CommissionRegulation(EC)No 1234/2008. C.I.z-Changes(Safety/Efficacy)ofHumanand VeterinaryMedicinalProducts-Othervariation C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including theRMP-Implementation of wording agreed by the competent authority | 10/11/2022 | 06/11/2023 | SmPC and Annex II | C.I.z-To update section4.9of theSmPC,toimplement thewordingrelatedtotheriskofnon-cardiogenic pulmonary oedema in amlodipine overdose. C.I.11.a-To update Annex II to reflect the fulfilment of ConditionB,assetoutbytheCommissionDecisionasan outcomeoftheassessmentfortheimpactoftheArticle 5(3)scientificopinion onnitrosaminesinhumanmedicinal products on the opinion adopted pursuant to Article 31 of Directive2001/83/ECforangiotensin-II-receptor antagonists (sartans) containing a tetrazole group. |

<div style=\"page-break-after: always\"></div>

| WS/2278/G   | Thiswas an applicationfor agroupofvariations following aworksharingprocedure according to Article20of CommissionRegulation(EC)No 1234/2008. B.III.1.a.3-Submission of a new/updated or deletion ofPh.Eur.Certificate ofSuitability to the relevantPh.Eur.Monograph-New certificate from a new manufacturer (replacement or addition) B.I.a.1.f -Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place                                                                                                                      | 27/10/2022   | n/a   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| WS/2256/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation(EC) No 1234/2008. B.II1.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificate of Suitability tothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specificationparametertothespecificationwithits corresponding test method B.I.b.2.a - Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure | 02/06/2022   | n/a   |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.2.a -Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate- Other changestoatestprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.f-Changein themanufacturerofASorofa startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacement or additionofasitewhere batchcontrol/testingtakesplace   |            |     |                                |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------|
| PSUSA/10344 /202106 | PeriodicSafetyUpdateEUSingleassessment- amlodipine / valsartan, amlodipine / hydrochlorothiazide/valsartan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/02/2022 | n/a | PRACRecommendation-maintenance |
| IG/1439/G           | Thiswasanapplicationforagroupofvariations. B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer A.4-Administrativechange-Changeinthename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor                                                                                                                                                                                                                                                                                                                                                                                                           | 15/10/2021 | n/a |                                |

<div style=\"page-break-after: always\"></div>

|           | intermediateusedin themanufactureof theASor manufacturerofanovelexcipient                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                 |                                    |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------------------|
| IG/1438/G | This was an application for a group of variations. A.7-Administrativechange-Deletionof manufacturing sites A.5.b-Administrative change-Change in the name and/oraddressof amanufacturer/importerof the finishedproduct,including quality control sites (excluding manufacturer for batch release) B.11.b.2.c.1-Change to importer,batch release arrangements and quality control testing of the FP - Replacementoradditionofamanufacturer responsible for importation and/or batch release - | 05/10/2021 | 29/09/2022 | Annex II and PL | Not includingbatch control/testing |
|           | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. C.1.11.z -Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation，includingtheRMP-Othervariation                                                                                                                                                                                                                   | 02/09/2021 | 11/10/2021 | Annex II        | WS/2109                            |
|           | This was an application for a group of variations. C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreedbythecompetentauthority C.1.11.a -Introduction of, or change(s) to, the                                                                                                                                                                                                     | 26/04/2021 | 11/10/2021 | Annex II        | IG/1383/G                          |

<div style=\"page-break-after: always\"></div>

|           | obligations and conditions of a marketing authorisation,including the RMP-Implementation of wordingagreedbythecompetent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     |           |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| WS/2041/G | Thiswasanapplicationforagroupofvariations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No 1234/2008. B.II.d.2.d -Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a-Change in test procedure for the finished product-Minorchangestoanapproved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 22/04/2021 | n/a | procedure |
|           | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. B.I.b.1.h -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionor replacement(excl.Biol.orimmunol.substance)of a specification parameter as a result of a safety or quality issue                                                                                                                                                                                                                | 15/04/2021 | n/a | WS/2019   |

<div style=\"page-break-after: always\"></div>

| WS/2022/G   | This was an applicationfor a group ofvariations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.c-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specificationparametertothespecificationwith its corresponding test method B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitability tothe relevantPh.Eur.Monograph-Updatedcertificate from an already approved manufacturer   | 15/04/2021   | n/a        |                 |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|
| WS/2023/G   | This was an applicationfor a group ofvariations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.2.c.2-Change to importer,batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s)takeplace,exceptbatch-                                                                                                                                                                                                                                                                                                                                   | 25/03/2021   | 11/10/2021 | Annex II and PL |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|          | release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.3.z-Change in the manufacturing process of thefinishedorintermediateproduct-Othervariation B.II.e.4.a - Change in shape or dimensions of the container or closure(immediate packaging)-Non- sterilemedicinal products                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |          |                                                                        |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------------------------------------------------------|
| A31/0099 | TheEuropeanCommissiontriggeredareferral under Article31ofDirective2001/83/EC andrequested the CHMP to assess the impact of nitrosamine impurities on the benefit-risk balance of valsartan-containing medicinalproducts and to issue arecommendation on whether therelevantmarketing authorisations should be maintained,varied, suspended or revoked. During theCHMPplenarymeetinginSeptember 2018,thescopeof thereferral hasbeenwidened to include all sartans with a tetrazole group in their molecularstructure(candesartan,irbesartan, losartan,olmesartan andvalsartan).The CHMP Opinionwasissuedon31January2019and the CommissionDecisionwas issued on2April 2019. In aletterdated29July2020,theEuropean CommissionrequestedtheEMAtoassesstheimpact of theoutcomeof theArticle5(3)assessmenton nitrosaminesadoptedon25June2020on the CHMP'sopinionof31January2019forthescientific assessment and review under Article 31 of Directive 2001/83/EC regarding angiotensin-II-receptor antagonists (sartans) containing a tetrazole group (EMEA/H/A-31/1471).The CHMP was requested to | 12/11/2020 | 12/02/2021 | Annex II | Pleasereferto the assessmentreport: CopaliaEMEA/H/A-31/1471/C/774/0099 |

<div style=\"page-break-after: always\"></div>

|         | the Marketing Authorisations shouldbevaried.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |          |           |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------|
| WS/1946 | Thiswasanapplicationforavariationfollowinga worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. B.II.b.3.z-Change in the manufacturing process of thefinishedorintermediateproduct-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                | 14/01/2021 | n/a        |          |           |
| IG/1319 | B.II.e.6.b -Change in any part of the (primary) packaging material not in contact with the finished productformulation-Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 07/12/2020 | n/a        |          |           |
|         | Thiswas anapplicationfor agroupofvariations. A.4-Administrative change-Change in the name and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateused in themanufacture of theASor manufacturer of a novel excipient B.I.a.1.f-Changein themanufacturerofASorofa startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacement or additionofasitewhere batch control/testing takes place B.I.b.1.h-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionor replacement(excl.Biol.orimmunol.substance)ofa | 20/10/2020 | 11/10/2021 | Annex II | IB/0112/G |

<div style=\"page-break-after: always\"></div>

| specification parameter as a result of a safety or quality issue B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate- Other changestoatestprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.z-Change in test procedure forAS or starting material/reagent/intermediate - Other variation B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilityto the relevantPh.Eur.Monograph-Updatedcertificate from an already approved manufacturer B.II1.1.a.2-Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2-Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer B.Ill.1.a.3-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-New certificatefrom a newmanufacturer(replacement or addition)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IG/1254/G   | Thiswas an applicationfor a groupofvariations.                                                                                                                                                                                                                                                                                                                                                                                                                        | 15/05/2020   | n/a        |          |           |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------|-----------|
| IG/1174/G   | Thiswas anapplicationfor a group of variations. A.5.b -Administrative change -Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excludingmanufacturerforbatchrelease) A.7-Administrative change-Deletion of manufacturingsites B.II.b.2.a - Change to importer, batch release arrangementsandqualitycontrol testingof theFP- Replacement/addition of a site wherebatch control/testingtakesplace | 11/12/2019   | n/a        |          |           |
|             | Thiswas an applicationfor agroupofvariations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. B.I.a.1.f-Changein themanufacturerofASorof a                                                                                                                                                                                                                                                                            | 31/10/2019   | 26/06/2020 | Annex II | WS/1656/G |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for the AS-replacement or addition of a site where batch control/testing takes place B.I.b.1.h -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionor replacement(excl.Biol.orimmunol.substance)ofa specification parameter as a result of a safety or quality issue B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionor replacement(excl.Biol.orimmunol.substance)ofa specification parameter as a result of a safety or quality issue B.I.b.2.a-Change in test procedure forAS or starting material/reagent/intermediate - Minor changesto anapprovedtestprocedure B.I.b.2.z-Change in test procedure for AS or startingmaterial/reagent/intermediate-Other   |            |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IG/1111/G | This was an applicationfor a group of variations. B.I.a.1.f-Change in themanufacturer of ASor of a starting material/reagent/intermediate for AS -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 08/08/2019 | n/a |

<div style=\"page-break-after: always\"></div>

| Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.III.1.a.3-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-New certificatefrom a newmanufacturer(replacementor addition)                                                                                           |            |            |                 |                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------------------|
| This was an application for a group of variations. A.7-Administrative change-Deletion of manufacturing sites B.II.b.1.a-Replacementor additionofa manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1-Change to importer,batch release arrangements and quality control testing of the FP - Replacementoradditionofamanufacturer responsibleforimportationand/orbatchrelease- | 16/07/2019 | 26/06/2020 | Annex II and PL | IG/1116/G Not including batch control/testing |
| C.I.11.a-Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including theRMP-Implementation of wordingagreedbythecompetentauthority                                                                                                                                                                                                                  | 05/07/2019 | n/a        |                 | IG/1112                                       |
| A.7-Administrative change-Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                       | 24/05/2019 | n/a        |                 | IG/1100                                       |
| A.7-Administrativechange-Deletionof                                                                                                                                                                                                                                                                                                                                                             | 24/05/2019 | n/a        |                 | IG/1099 manufacturing sites                   |

<div style=\"page-break-after: always\"></div>

| IG/1098   | B.IIl.1.a.2-Submissionofanew/updatedor deletion ofPh.Eur.Certificateof Suitability to the relevant Ph.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                      | 29/04/2019   | n/a        |                            |                                            |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------|--------------------------------------------|
| IG/0986   | C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                          | 17/10/2018   | 02/04/2019 | Annex II, Labelling and PL |                                            |
|           | Thiswas an applicationfor a group of variations. B.I.a.1.f -Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place B.III.1.a.1 -Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from | 10/09/2018   | n/a        |                            | IG/0975/G an already approved manufacturer |
|           | Thiswas an applicationfor a group of variations. B.II.c.1.a-Change in the specification parameters and/or limits of an excipient -Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/orlimitsof thefinishedproduct-Tighteningof specification limits B.II.d.1.a-Change in the specification parameters and/or limits of the finished product - Tightening of specification limits          | 21/08/2018   | n/a        |                            | IG/0958/G                                  |

<div style=\"page-break-after: always\"></div>

|        | B.II.d.1.c-Change in the specification parameters and/orlimitsof thefinishedproduct-Addition of a newspecificationparameter to the specification with its corresponding test method                                                                                                                                                                                                                            |            |            |                        |           |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------|
|        | A.5.b - Administrative change - Change in the name and/oraddressofamanufacturer/importerofthe finished product, including quality control sites (excludingmanufacturerforbatchrelease)                                                                                                                                                                                                                         | 21/06/2018 | n/a        |                        | IG/0947   |
| T/0097 | Transfer ofMarketingAuthorisation                                                                                                                                                                                                                                                                                                                                                                              | 16/05/2018 | 04/06/2018 | SmPC, Labelling and PL |           |
|        | C.I.3.a - Change(s) in the SPC, Labelling or PL intendedtoimplementtheoutcomeofaprocedure concermingPSURorPASSortheoutcomeofthe assessmentdoneunderA45/46-Implementationof wording agreed by the competent authority                                                                                                                                                                                           | 17/04/2018 | 04/06/2018 | SmPC and PL            | IG/0910   |
|        | Thiswas an applicationfor agroupofvariations followingaworksharingprocedure accordingto Article20 of CommissionRegulation(EC)No 1234/2008. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters | 15/03/2018 | n/a        |                        | WS/1291/G |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate -Deletion of a test procedure for the AS or a starting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.b -Change in test procedure forAS or startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.b-Change in test procedure forAS or startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate,if an alternativetest procedure is already authorised B.I.b.2.b-Change in test procedure forAS or startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.b -Change in test procedure forAS or startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.b-Change in test procedure forAS or startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | procedure is already authorised B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate   |            |            |             |                                |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------|
| IG/0863             | A.4-Administrative change-Change in thename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateused in themanufactureof theASor manufacturerofanovelexcipient                            | 01/12/2017 | n/a        |             |                                |
| IG/0805             | A.7-Administrative change-Deletion of manufacturing sites                                                                                                                                                                                 | 23/05/2017 | n/a        |             |                                |
| PSUSA/10344 /201606 | PeriodicSafetyUpdateEUSingleassessment- amlodipine/valsartan,amlodipine/ hydrochlorothiazide/valsartan                                                                                                                                    | 09/03/2017 | n/a        |             | PRACRecommendation-maintenance |
| IG/0776             | B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.Certificateof Suitabilitytothe relevantPh.Eur.Monograph-Updatedcertificate fromanalreadyapprovedmanufacturer                                                                  | 23/02/2017 | n/a        |             |                                |
| WS/1080             | Thiswas anapplicationfor avariationfollowing a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. C.I.z-Changes (Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Other variation              | 23/02/2017 | 30/01/2018 | SmPC and PL |                                |

<div style=\"page-break-after: always\"></div>

| IG/0751/G   | Thiswas an applicationfor a groupofvariations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 15/12/2016   | n/a   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IG/0727/G   | This was an applicationfor a group of variations. B.I.a.1.f-Changein themanufacturerofASorofa startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltesting arrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changestoanapprovedtestprocedure B.I.b.2.a - Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure | 14/09/2016   | n/a   |
| IG/0707     | B.I.a.1.f -Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 21/07/2016   | n/a   |

<div style=\"page-break-after: always\"></div>

|         | batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0706 | B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitability tothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 21/07/2016 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| WS/0709 | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. Changesrelated totheamlodipinecomponent Updateofsection4.2oftheSmPCtoincluderevised dosing recommendations in patients with hepatic impairment and in elderly patients. Changesrelatedtothevalsartancomponent Updateofsections4.2and4.3of theSmPCto removethecontraindicationrelatedtopatientswith severe renal impairment andpatients undergoing dialysisandsection4.8oftheSmPCtoupdatethe Preferred Term asperMedDRAversion17. The Package Leaflet has been updated accordingly. Inaddition,theMAHtooktheopportunity to implementminoreditorial changesintheSmPCand thePackageLeaflet C.I.4 -Change(s)in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 26/03/2015 | 05/05/2015 | SmPC and PL | Theremoval of thecontraindicationrelatedtopatientswith severe renal impairment and patients undergoing dialysis, iseditorialinnatureandisimplementedtoalignthe productinformationwiththedecisionfromArticle30 Referralprocedure(EMEAprocedurenumber:EMEA/H/A- 30/998)concludedfor Diovan inNov2008.As an oversight, thiswasnot applied to theExforgeproduct information at the time. Theposologysection is updated tohighlight thatwhen switching eligible hypertensive patients with hepatic impairmentorelderlyhypertensivepatientstoamlodipine or Exforge, the lowest available dose of amlodipine monotherapyoroftheamlodipinecomponent,respectively, should be used. |
| IG/0539 | C.I.1.a - Change(s) in the SPC, Labelling or PL intended toimplementtheoutcomeofaUnion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 27/03/2015 |            | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | referral procedure - The product is not covered by thedefinedscope of theprocedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IG/0536/G | This was an application for a group of variations. B.1.b.1.c-Change in thespecificationparameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.d-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Deletionofanon- significant specification parameter (e.g. deletion of an obsoleteparameter) B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure B.1.b.2.a-Change in test procedure forAS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificateof Suitability tothe relevant Ph.Eur.Monograph-Updated certificate from an already approved manufacturer B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer | 11/03/2015 | n/a |
| IG/0528/G | Thiswas anapplicationfor a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 17/02/2015 | n/a |

<div style=\"page-break-after: always\"></div>

|           | A.4-Administrative change-Changein thename and/or address of a manufacturer or an ASMF holder orsupplieroftheAS，startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturer of a novel excipient B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method   |            |            |                        |                                                                      |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------|
| IG/0523/G | Thiswas an applicationfor a group of variations. A.5.b-Administrativechange-Change in thename and/or address of a manufacturer/importer of the finished product, including quality control sites (excludingmanufacturerforbatchrelease) A.7-Administrative change-Deletion of manufacturing sites                                                                                                                                                                                                                                                                                           | 22/01/2015 | n/a        |                        |                                                                      |
| IG/0514   | A.1-Administrativechange-Changeinthename and/oraddressoftheMAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 16/12/2014 | 05/05/2015 | SmPC, Labelling and PL |                                                                      |
| WS/0632/G | This was an application for a group of variations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                          | 23/10/2014 | n/a        |                        | Toimplement changesin themanufacturingprocessof the active substance |

<div style=\"page-break-after: always\"></div>

| To implement changes in the manufacturing process of the active substance. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z-Changes in the manufacturing process of theAS-Other variation B.I.a.2.z-Changes in the manufacturing process of the AS-Other variation B.I.a.2.z-Changes in the manufacturing process of the AS-Other variation B.I.a.2.a-Changes in the manufacturing process of theAS-Minor change in themanufacturingprocess of the AS B.I.a.2.a-Changes in the manufacturing process of theAS-Minor change in the manufacturingprocess of the AS B.I.a.2.a-Changes in the manufacturing process of theAS-Minor change in themanufacturingprocess of the AS B.I.a.2.a-Changes in the manufacturing process of theAS-Minor change in the manufacturingprocess of theAS B.I.a.4.z-Change toin-processtestsorlimits applied during the manufacture of the AS - Other variation B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| WS/0630/G   | Thiswas an applicationfor a groupof variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Replacementof2 testmethodsfor anactive substance intermediate. Toincude a minor change in a test method for an activesubstanceintermediate. Toadd3testmethodsfor an activesubstance intermediate. To change the specification parameter for an active substance intermediate. B.I.b.2.e -Change in test procedure forAS or starting material/reagent/intermediate- Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changestoanapprovedtestprocedure B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specificationparameter to thespecificationwithits corresponding test method B.I.b.1.b-Change in the specification parameters and/or limits of an AS, starting   | 23/10/2014   | n/a   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.I.b.2.e-Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its correspondingtestmethod   |            |     |                                                                                                                                                                                                                                                                    |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0629/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Toreplace3testmethodsfor anactivesubstance intermediate. Toincludeaminorchangetoan approved test procedure for an active susbtance intermediate. Toaddatestmethodoranactivesubstance intermediate. Toadd2alternativetestmethodsforanactive substance intermediate. B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other                                                                                                               | 23/10/2014 | n/a | Toreplace3 testmethodsfor anactivesubstance intermediate. Toincludeaminorchangetoanapprovedtestprocedure foran activesusbatcneintermediate. Toadd a testmethod or an activesubstanceintermediate. Toadd 2alternativetestmethodsfor anactivesubstance intermediate. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| changesto a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.a-Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent -Addition of a new specification parameter to the specification with its   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| WS/0631/G   | Thiswas an applicationfor agroupofvariations followingaworksharingprocedure according to Article20of CommissionRegulation(EC)No 1234/2008. Toadd an alternativemanufacturerofAS intermediates. ToincreasethebatchsizesforASintermediatesfor thenewmanufacturingsite Todelete a manufacturing siteforASintermediates. B.I.a.1.z-Change in the manufacturer ofASor of a startingmaterial/reagent/intermediateforAS-Other variation B.I.a.3.a-Change inbatch size(including batch size ranges)ofASorintermediate-Upto10-fold increase compared to the originally approved batch size A.7-Administrativechange-Deletionof   | 23/10/2014   | n/a        |             |                                                                                                                           |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------|
| A31/0069    | On17April2013,furthertotheemergence ofnew evidencefromthescientificliteratureondualRAS blockadetherapyandgiventheseriousnessof the identifiedsafetyconcerns,theItalianMedicines Agency(AIFA)initiated areviewunderArticle31of CouncilDirective2001/83/EC,requestingthe PharmacovigilanceRiskAssessmentCommittee (PRAC) to issue a recommendation on the benefit- risk of dual RAS blockade therapy through the combined use of angiotensin-converting enzyme inhibitors (ACE-inhibitors), angiotensin II receptor                                                                                                       | 22/05/2014   | 04/09/2014 | SmPC and PL | ForfurtherinformationpleaserefertotheRenin- angiotensin-system (RAS)-acting agents Article 31 referral -Assessmentreport. |

<div style=\"page-break-after: always\"></div>

|           | blockers (ARBs) or aliskiren and to determine whether any regulatory measures should be taken on themarketing authorisationsof theproducts involved in thisprocedure.                                                                                                                                                                                                                               |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0424/G | Thiswas an applicationfor a group of variations. A.7-Administrativechange-Deletion of manufacturingsites A.7-Administrativechange-Deletionof manufacturingsites B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for the AS-replacement or addition of a site where batch control/testing takes place | 26/03/2014 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| WS/0516   | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. Updateofsection4.8oftheSmPCtoincludethe ADR'bullous dermatitis'. C.I.4 -Change(s)in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                          | 20/03/2014 | 04/09/2014 | SmPC | TheMAHhassubmittedacomprehensivereportwiththe purpose of reviewing the potential association of skin events with valsartan containing medications, including ExforgeandExforgeHCTandrespectiveclones.Itis consideredjustifiedtoupdatethelistofADRsinsection4.8 undesirableeffects'oftheExforgeSmPCandExforgeHCT SmPCandtheirrespectiveclonesbasedonadditional informationfromasmallnumberofpost-marketingcases reporting bullous rash occurring with valsartan. This amendmentdoesnotchange thebenefitriskbalancefor these products which remains positive. |
| WS/0495/G | This was an application for a group of variations                                                                                                                                                                                                                                                                                                                                                   | 20/02/2014 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. - change in the specification limits of some intermediatesusedinthemanufactureoftheactive substance, -additionofanewspecificationparameterswith theircorrespondingtestmethodstothespecification ofsomeintermediatesusedinthemanufactureof the active substance and - change in test procedures for some intermediates used in themanufacture of the activesubstance. B.I.b.1.b-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Tightening of specification limits B.I.b.1.b-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c-Changein the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.b.2.e-Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e-Change in test procedure for AS or starting material/reagent/intermediate- Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or starting material/reagent/intermediate - Other changes to a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in testprocedure forAS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IG/0377/G   | This was an applicationfor a group ofvariations.                                                                                                                                                                                                                                                                                                                | 22/11/2013   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0461     | Thiswas an applicationfor avariationfollowing a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Updateofsection4.5oftheSmPCtoincludefurther information regarding an interaction between valsartan and lithium. C.I.4 -Change(s)in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 21/11/2013   | 04/09/2014 | SmPC | The MAH has reviewed the clinical databases of four large outcomes studies(Val-HeFT,Value,Valiant, and Navigator) for adverse eventreports of lithium toxicity.Further,the NovartisSafetyDatabase(ARGUS)wassearchedfor all caseswherebothvalsartanandlithiumwerereported as co-administered,andaliterature searchwasperformedfor published studies. Theavailabledatasuggestapossiblereversibleinteraction betweenvalsartanandlithium,althoughtheexact mechanismhasnotbeen established.The dataidentified arelimited andnoconfirmatoryevidencewas available from the clinical trialsperformed. TheSmPChasbeenupdatedtoinformprescribersof the factthatreversibleincreasesinserumlithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensinII receptor antagonistsincludingvalsartan.Therefore,careful monitoringofserumlithiumconcentrationsis recommended during concomitant use. If a diurectic is also used, the risk of lithium toxicity may presumably be |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                       | increased further.                                                                                   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------|
| IG/0349 | B.III.1.a.4-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Deletion of certificates (incasemultiplecertificatesexistpermaterial)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 27/08/2013 | n/a        |                       |                                                                                                      |
| WS/0360 | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Update ofSmPC sections 4.2,4.3,4.4 and 4.5 to reflect that the concomitant use of Angiotensin II Receptor Blockers (ARBs) orAngiotensin-Converting- Enzyme inhibitors (ACEi) with aliskiren is contraindicated in patients with renal impairment and in patients with diabetes mellitus. Further, section4.4oftheSmPChasbeenupdated toinform prescribers that caution is required, and monitoring ofbloodpressure,renalfunctionandelectrolytesis recommended, when co-administering agents acting onthereninangiotensinaldosteronesystem(RAAS) i.e.ACEi, ARBs or aliskiren as a direct renin inhibitor. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update theSmPC,Annex II and thePackage Leaflet in line with thelatestQRDtemplate,toimplement minor editorial changes in the Package Leaflet and to add thecontactdetailsoftheCroatianlocal representative in the Package Leaflet. | 27/06/2013 | 31/07/2013 | SmPC, Annex II and PL | Please refer to the Scientific Discussion \"Exforge-Copalia- Dafiro-Imprida-EMEA-H-C-xxxx-WS-360-AR\". |

<div style=\"page-break-after: always\"></div>

|           | of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0270   | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 01/02/2013 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IG/0248   | C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/12/2012 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IG/0233   | B.III.1.a.2-Submission of a new or updated Ph.Eur. Certificate of Suitability to therelevantPh.Eur. Monograph - Updated certificate from an already approvedmanufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 13/11/2012 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| WS/0249/G | This was an application for a group of variations following a worksharing procedure according to Article 20of CommissionRegulation(EC)No 1234/2008. WS-0249-Gwasagroupofvariationsconsistingof two Type II variations following a worksharing procedure according to Article 20 of Commission Regulation(EC)No1234/2008asfollows: Variation1:Updateofsection4.4of theSmPC to add a new warning regarding the risk of 'angioedema'related to thevalsartancompound. Further, the MAH took the opportunity to update the wording of the existing warnings in section 4.4 of the SmPC ('renal artery stenosis', 'heart failure', and 'aorticandmitralvalvestenosis')forincreased | 20/09/2012 | 25/10/2012 | SmPC and PL | The safety update of the SmPC and Package Leaflet was basedonareviewoftheMAH'ssafetyandclinical trialdata bases, published literature for both the amlodipine and valsartancomponents,arecommendationbytheUSFDA as well as the recent revised and harmonised amlodipine monotherapy product information that was agreed by the CHMPaspartofthearticle30referralprocedure EMEA/H/A-30/1288on 21 July 2011. TheMAHpresented anextensive analysisofboth 'angioedema requiring intubation' and'previous angioedemawithorwithoutACE-inhibitoruse'，basedon datafromtheirsafetydatabaseand theclinicaltrial database. In addition, the MAH provided the outcome of a literaturesearch.Fromthesafetydatabase，42patientsout of 1469'angioedema' reports (2.86%) required intubation. Intheclinical trial databasetherewasasmall number of |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| clarity.ThePackageLeaflethasbeenupdated accordingly; Variation 2: Update of sections 4.2,4.3,4.4,4.7, 4.8,5.1and5.2oftheSmPCtoharmonisethe existingwordingrelatedtotheamlodipinecompound inlinewiththelatestSmPCof Norvasc(amlodipine monotherapy) approved as part of arecent article 30 procedure EMEA/H/A-30/1288. The Package Leaflet hasbeen updated accordingly.In addition,the MAH tooktheopportunitytoupdatethecontactdetailsfor the local representatives for Luxemburg and Malta in the Package Leaflet. C.I.4-Variationsrelatedtosignificantmodifications of theSPCdueinparticular tonewquality,pre- clinical, clinical or pharmacovigilance data C.I.4-Variationsrelatedtosignificantmodifications   | of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |             | \"heart failure\"and\"aortic and mitral valve stenosis\")were alsomade aspart of thisprocedure inordertoprovide further clarity to thehealth careprofessional. In addition, the MAH took the opportunity to update the amlodipinesectionsoftheSmPCinaccordancewiththe harmonised product informationfor Norvasc(amlodipine monotherapy).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0248/G | Thiswas anapplicationfor agroupofvariations followingaworksharingprocedureaccordingto Article20of CommissionRegulation(EC)No 1234/2008. WS-0248-Gwasagroupofvariationsconsisting of two Type II variations following a worksharing procedureaccordingtoArticle20ofCommission Regulation(EC)No1234/2008asfollows: Variation1:Updateofsection4.5of theSmPCto add information about thepotential druginteraction between amlodipine andsimvastatin,and update of the existing amlodipine information in section 4.5 in linewiththereviseddruginteractionssectionfor Norvasc(amlodipinemonotherapy).ThePackage Leaflet has been updated accordingly; Variation2:Updateofsection4.5of theSmPCto addinformationaboutthepotentialdruginteraction betweenvalsartanandinhibitorsoftheuptake transporter(rifampicin,ciclosporin)or efflux transporter (ritonavir). The Package Leaflet has been updated accordingly. C.I.4-Variationsrelated to significant modifications | 19/07/2012 | 23/08/2012 | SmPC and PL | Administrationof amlodipinewithgrapefruit orgrapefruit juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood pressureloweringeffects. Concomitantuseofamlodipinewithstrongormoderate CYP3A4 inhibitors(protease inhibitors,azole antifungals, macrolideslikeerythromycinorclarithromycin,verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these pharmacokinetic variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required. ThereisnodataavailableregardingtheeffectofCYP3A4 inducerson amlodipine.TheconcomitantuseofCYP3A4 inducers (e.g. rifampicin, Hypericum perforatum) may give alowerplasmaconcentrationofamlodipine.Amlodipine shouldbeusedwithcautiontogetherwithCYP3A4 inducers. Co-administrationofmultipledosesof10mgamlodipine with80mgsimvastatinresultedina77%increasein exposuretosimvastatincompared tosimvastatin alone.It is recommended to limit the dose of simvastatin to 20 mg daily in patients on amlodipine. In animals, lethal ventricular fibrillation and cardiovascular |

<div style=\"page-break-after: always\"></div>

|           | of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data C.I.4-Variationsrelatedtosignificantmodifications of theSPCdue inparticular to newquality,pre- clinical, clinical or pharmacovigilance data                                                                                                                 |            |            | collapseareobservedinassociationwithhyperkalaemia after administration of verapamil and intravenous dantrolene.Due toriskofhyperkalaemia,it is recommendedthattheco-administrationofcalcium channel blockerssuch as amlodipinebe avoidedinpatients susceptibletomalignanthyperthermiaandinthe management of malignanthyperthermia. In clinical interaction studies,amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or ciclosporin. Theresultsof an invitro study withhuman liver tissue indicate that valsartan is a substrate of the hepatic uptake transporterOATPiB1andofthehepaticeffluxtransporter MRP2.Co-administration ofinhibitors of theuptake transporter(rifampicin,ciclosporin)or effluxtransporter (ritonavir) may increase the systemic exposure to   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0209/G | This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.h-Changes to anexistingpharmacovigilance system as described in the DDPS - Other change(s) totheDDPSthatdoesnotimpactontheoperationof the pharmacovigilance system | 17/08/2012 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| WS/0282   | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008.                                                                                                                                                                                                                        | 19/07/2012 | 19/07/2012 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | toadd anewspecificationparameterforimpuritiesin the active substance. B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specificationparametertothespecificationwithits correspondingtestmethod                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |      |                                                                                                           |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------|
| IG/0199/G | This was an application for a group of variations. B.I.a.1.f-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place A.5.b-Administrative change-Change in the name and/oraddressof amanufacturerof thefinished product,including quality control sites(excluding manufacturerforbatchrelease) B.Ill.1.a.2-SubmissionofaneworupdatedPh.Eur. CertificateofSuitabilitytotherelevantPh.Eur. Monograph-Updatedcertificatefrom analready approved manufacturer | 09/07/2012 | n/a        |      |                                                                                                           |
| WS/0251/G | Thiswas an applicationfor a group of variations followingaworksharingprocedureaccordingto                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 24/05/2012 | 28/06/2012 | SmPC | The safety of amlodipine in human pregnancy has not been established.Reproductivestudiesinratsandmicehave |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Article 20 of Commission Regulation (EC) No 1234/2008. WS-0251-G is a group of two variations (one type II &onetypeIB)followingaworksharingprocedureas follows: - Type II variation: Update of section 4.6 of the SmPCwithwording onfertility in linewiththeSmPC for Diovan (valsartan monotherapy) and 5.3 of the SmPCtoimplement thechangesto theSmPCfor Diovan that was approved as part of a recent Article 30 (referral) procedure; -TypeIBvariation:Update of sections 4.6and5.3 of theSmPCtoimplementthechangestotheSmPCfor Norvasc(amlodipinemonotherapy)thatwas approved as part of a recent Article 30 (referral) procedure. C.I.1.b - Change in the SPC, Labelling or PL following areferralprocedure-Theproduct isnot coveredby the defined scope of the referral but the change implementstheoutcomeofthereferralandnonew additional data aresubmittedbytheMAH C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is 6 times the maximum recommendedhumandoseonamg/m2basis(calculations assume an oral dose of 320 mg/day and a 60-kg patient). Non-clinicaldatarevealnospecialhazardforhumans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential. Inrats,maternallytoxicdoses(600mg/kg/day)during the lastdaysofgestation andlactationledtolowersurvival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6).These doses in rats(600mg/kg/day)are approximately18 times the maximumrecommended humandoseonamg/m2basis(calculations assume an oraldose of320mg/day and a60-kgpatient). In non-clinical safety studies,high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit)andevidenceofchangesinrenal haemodynamics (slightly raised plasma urea, and renal tubularhyperplasia andbasophilia inmales).These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m2basis(calculations assume anoral doseof320 mg/day and a 60-kg patient). Inmarmosetsatsimilardoses,thechangesweresimilar thoughmoresevere,particularlyin thekidney wherethe changesdeveloped toanephropathywhichincludedraised urea and creatinine. Hypertrophy of the renal juxtaglomerular cells was also seen inboth species.All changes were considered tobe caused by the pharmacological action of valsartan which   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                                  | produces prolonged hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seemtohaveanyrelevance.                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0061    | Minor change in labelling or package leaflet not connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                                                                                                                                                                            | 02/05/2012 | 28/06/2012 | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IG/0148/G | Thiswasanapplicationforagroupofvariations. C.I.9.e-Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the majorcontractualarrangementswithotherpersons or organisationsinvolvedinthefulfilment of pharmacovigilanceobligationsanddescribedinthe DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) totheDDPSthatdoesnotimpactontheoperationof | 22/02/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| R/0049    | Renewal of themarketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                | 22/09/2011 | 21/11/2011 | SmPC, Annex II, Labelling and PL | BasedontheCHMPreviewof theavailableinformation and on the basis of a re-evaluation of the benefit risk balance, theCHMPwasof the opinionthatthequality,safetyand efficacyofthismedicinalproductcontinuestobe adequatelyandsufficientlydemonstratedandtherefore considered thatthebenefitriskprofileofCopaliacontinues to be favourable. The CHMP recommended the renewal of the Marketing Authorisation for Copalia, subject to the conditions as laid down in Annex II to the Opinion.The CHMPwas also of the opinionthattherenewal canbegrantedwithunlimited |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |             | validity. The renewal required amendments to the terms of the CommunityMarketingAuthorisationbasedon theCHMP's requesttoimplement thelatestQRDtemplate.Therefore, theCHMPrecommendedthefollowingannexestobe amended:I,II,IIIA andIIIB.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0100/G | Thiswas anapplicationfor agroupofvariations followingaworksharingprocedureaccordingto Article20ofCommissionRegulation(EC)No 1234/2008. UpdateofSummaryofProductCharacteristics and Package Leaflet Thiswas an applicationfor agroupofvariations followingaworksharingprocedureaccordingto Article20ofCommissionRegulation(EC)No 1234/2008. C.I.4-Variations related to significant modifications of the Summary of Product Characteristics due in particular to new quality, pre-clinical, clinical or pharmacovigilancedata C.I.4-Variationsrelatedtosignificantmodifications of theSPC due inparticular to new quality,pre- clinical,clinicalorpharmacovigilancedata C.I.4-Variationsrelatedtosignificantmodifications of theSPCdue inparticular tonewquality,pre- clinical, clinical or pharmacovigilance data C.I.4-Variationsrelatedto significant modifications | 23/06/2011 | 27/07/2011 | SmPC and PL | WS-0i00-Gwassubmittedforagroupofvariations consisting of three Type II variations following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Thefollowingvariationwasnotconsideredacceptableby the CHMP: -Variation1(scope as applied forby theMAH):Update of section5.1oftheSmPCwithinformationonefficacyin patientswithstage2hypertensionandblackpatients basedonstudiesVAA2402andVAA2403. Thefollowingvariationswereconsideredacceptablebythe CHMP: -Variation2:Deletionof thecurrentparagraphinsection 5.1oftheSmPCthatprovidesinformationontherelative efficacyofvalsartan/amlodipine80/5mgcomparedto amlodipine10mginrelationtotheincidenceofoedema.In addition,theMAH tooktheopportunitytoupdatetheSmPC inlinewiththelatestQRDtemplate and toupdate the contactdetailsof thelocal representativesinthePackage Leaflet. -Variation3:Updateofsection5.1oftheSmPCwith informationonefficacy in obesepatients. [crossreferencetoScientificdiscussionofadoptedCHMP Assessment Report]. |

<div style=\"page-break-after: always\"></div>

|           | clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |     |                              |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------|
| IG/0088/G | This was an application for a group of variations. C.I.9.e-Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the majorcontractual arrangementswithotherpersons or organisations involved in the fulfilment of pharmacovigilanceobligations anddescribedinthe DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of                                                                                                                                                                                                                 | 11/07/2011 | n/a | the pharmacovigilance system |
| IG/0074/G | This was an application for a group of variations. B.I.a.2.a-Changes in themanufacturing process of theAS-Minor change in themanufacturingprocess of theAS B.I.b.1.c -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting | 17/06/2011 | n/a |                              |

<div style=\"page-break-after: always\"></div>

|           | material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.2.a - Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changes to an approved testprocedure B.I.b.2.a-Change in test procedure forAS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a -Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure   |            |            |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| IG/0058   | B.III.1.a.2-Submission of a new orupdated Ph.Eur. Certificate of Suitability to therelevantPh.Eur. Monograph - Updated certificate from an already approvedmanufacturer                                                                                                                                                                                                                                                                                                                                                   | 13/04/2011 | n/a        |
| WS/0088/G | This was an application for a group of variations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. to change the specification limit for an impurity in the active substance ; toaddnewtestproceduresfortheactivesubstance toaddnewspecificationsin the activesubstance todeletea testprocedurefortheactive substance. B.I.b.1.c-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew                      | 17/02/2011 | 17/02/2011 |

<div style=\"page-break-after: always\"></div>

|           | specification parameter to the specification with its corresponding test method B.I.b.1.b-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.2.e-Change in test procedure forAS or starting material/reagent/intermediate- Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e-Change in testprocedure forAS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.b -Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changes to a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate   |            |     |          |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|
| IG/0032/G | This was an application for a group of variations. ToupdatetheDetailedDescriptionofthe Pharmacovigilance System (DDPS) to version 9.0, to include:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 21/12/2010 | n/a | Annex II |

<div style=\"page-break-after: always\"></div>

|           | - a change in the deputy of the Qualified Person for Pharmacovigilance (QPPV); - a change in the major contractual arrangements. - administrative changes not impacting the operation of the pharmacovigilance system. AnnexII.Bhasalsobeenupdatedwiththelatest wording as per October 2010 CHMPprocedural announcement. C.I.9.c-Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-upprocedureoftheQPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons ororganisationsinvolvedinthefulfilmentof pharmacovigilanceobligations anddescribedinthe DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system   |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IG/0028   | B.II.b.1.a-Replacement or addition of a manufacturing site for the Fp - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 12/11/2010 | n/a |
| IB/0048/G | Thiswas an applicationfor a group of variations. B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changes to a test procedure(including replacement                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 24/06/2010 | n/a |

<div style=\"page-break-after: always\"></div>

|           | or addition)for the ASora starting material/intermediate B.III.1.a.1 -Submission of a new or updated Ph. Eur. Certificate of Suitability to therelevantPh.Eur. Monograph - New certificate from an already approved manufacturer B.III.1.a.2-Submission of a new or updatedPh.Eur. Certificate of Suitability to therelevantPh.Eur. Monograph - Updated certificate from an already approved manufacturer B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Deletionof anon- significant specification parameter (e.g. deletion of anobsoleteparameter) B.I.b.2.a-Change in testprocedure forAS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.1.b -Change in the specification parameters and/or limits of an AS, starting   |            |            |                        |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IA/0047/G | This was an applicationfor a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 21/05/2010 | 21/05/2010 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|         | the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within therange of the currently approvedpack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes   |            |            |          | tablets,ampoules,etc.)in a pack-Change within   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-------------------------------------------------|
|         | Changes to QPPV UpdateofDDPS(Pharmacovigilance)                                                                                                                                                                                                                                                                                                                                                                                                      | 18/02/2010 | 19/03/2010 | Annex II | II/0046                                         |
|         | IA_07_b_01_Replacement/add. of manufacturing site:Primarypackaging site-Solidforms                                                                                                                                                                                                                                                                                                                                                                   | 27/11/2009 | n/a        |          | IA/0044                                         |
|         | Change in the manufacturing process of the drug substanceValsartan;addition of analternative process for the synthesis of one of the compound used. Quality changes                                                                                                                                                                                                                                                                                  | 19/11/2009 | 25/11/2009 |          | I1/0042                                         |
| IA/0045 | IA_07_a_Replacement/add.ofmanufacturingsite: Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                | 25/11/2009 | n/a        |          |                                                 |
|         | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                                                                                                                                                                                                                                                                                           | 24/11/2009 | n/a        | SmPC     | IB/0043                                         |
|         | To tighthen the specification,modify testprocedures andintroducenew onesforthe active substance                                                                                                                                                                                                                                                                                                                                                      | 24/09/2009 | 05/10/2009 |          | I1/0038                                         |

<div style=\"page-break-after: always\"></div>

|         | valsartaninordertoupdate theTestingMonograph of valsartan. Quality changes                                                                                                                                                                                                                                                                                                     |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0041 | IA_11_a_Change inbatchsize of active substance or intermediate-upto10-fold                                                                                                                                                                                                                                                                                                     | 13/08/2009 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0040 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph.Eur.cert.avail.)                                                                                                                                                                                                                                                                                | 28/07/2009 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0039 | IA_o9_Deletionofmanufacturingsite                                                                                                                                                                                                                                                                                                                                              | 28/07/2009 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0035 | TheMAH appliedfor anupdateof theSPCsection 4.6aswell asPLsection2 toimplement theCHMP recommendation on a harmonised labelling relating totheuseofAngiotensinIIReceptorAntagonists during pregnancy and lactation. Furthermore, minor typographical changes have been introduced to SPC sections 4.3 and 4.4. Update of Summary of Product Characteristics and Package Leaflet | 19/02/2009 | 27/03/2009 | SmPC and PL | AvailabledataregardinguseofAlIRAsduringlactation have been assessed. There are no concrete data to support the contraindication of use of AlIRAs during breast-feeding. AllAlIRA agentswerefound inthemilkof lactatingratsbut nohuman data about their transferintobreast milk are available.There isonly a theoreticalpresumption of low transport according to theirhighplasmaproteinbinding and low oral availability. A harmonised wording recommendinganaltemativetreatmentwithbetter establishedsafetyprofilesduringbreast-feeding,especially whilenursing a newborn orpreterminfant,hasbeen includedin thesection4.6oftheSPCandsection2of the PL. |
| IB/0037 | IB_14_b_Change in manuf.of active substance without Ph.Eur.certificate-new manufacturer                                                                                                                                                                                                                                                                                        | 13/03/2009 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0036 | IA_04_Change in name and/or address of a manuf. of the active substance(no Ph.Eur.cert.avail.)                                                                                                                                                                                                                                                                                 | 24/02/2009 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IB/0032   | IB_14_b_Changeinmanuf.ofactivesubstance withoutPh.Eur.certificate-newmanufacturer                                                                                          | 31/10/2008   | n/a   |         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------|
|           | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                           | 23/10/2008   | n/a   | IA/0034 |
|           | IA_11_a_Change in batch size of active substance or intermediate-up to10-fold                                                                                              | 23/10/2008   | n/a   | IA/0033 |
|           | IB_33_Minor change in the manufacture of the finished product                                                                                                              | 25/07/2008   | n/a   | IB/0030 |
| IB/0029   | IA_O8_a_Change in BR/QC testing - repl./add. of batch control/testing site IB_O7_c_Replacement/add.ofmanufacturingsite: All othermanufacturing operations ex.batch release | 23/07/2008   | n/a   |         |

<div style=\"page-break-after: always\"></div>

| IA/0028   | IA_07_a_Replacement/add.ofmanufacturing site: Secondary packaging site IA_07_b_01_Replacement/add. of manufacturing site:Primarypackagingsite-Solidforms                                                                                                                                         | 10/07/2008   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0027   | IA_32_a_Change inbatch size of thefinishedproduct - up to 10-fold                                                                                                                                                                                                                                | 07/07/2008   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0025   | IB_12_b_02_Change in spec.of active subst./agent inmanuf.of active subst.-testparameter                                                                                                                                                                                                          | 03/07/2008   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0026   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph.Eur.cert.avail.)                                                                                                                                                                                                  | 24/06/2008   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0020   | TheMAH appliedfor anupdateof theSPCsections 4.3, 4.4, and 4.6 as well as PL section 2 to implementtheCHMPrecommendationona harmonised labellingrelating to theuseofACE inhibitorsandAngiotensinIIReceptorAntagonists during pregnancy. UpdateofSummaryofProductCharacteristicsand PackageLeaflet | 24/04/2008   | 10/06/2008 | SmPC and PL | Cooper'sstudypublishedintheNEJMinJune2006 identifiedasignalofincreasedriskofcongenital malformations, particularly cardiac defects after exposure to ACE inhibitors during the first trimester of pregnancy. Sincetheroleofconfoundingfactorssuchasdiabetes and hypertensioncannotbeaccuratelydefinedbasedonthe available data,the teratogenicpotential ofACEinhibitorsis not demonstrated, even though data suggest that such exposure cannot be considered as safe and should be avoided. There arefewer dataregardingtherisks associatedwith first trimester exposure to Angiotensin II receptor antagonists(AIIRAs)thanforACEinhibitors.Nevertheless, there isnoevidencethattheriskis lowerforAIIRAs,and it is consideredthat any conclusions onACEinhibitors are also valid for AIIRAs. Therefore,the existing contraindicationforthe9-month |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                       |            |            |                        | pregnancy was revised in order to delete the contraindication during the 1st trimester of pregnancy, but toremainthecontraindicationforthe2nd and3rd trimester of pregnancy.In addition, a harmonisedwording regarding pregnancy across the class was introduced.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0024 | IA_15_a_Submission of Ph.Eur.certificate for active substance - approved manufacturer                                                                 | 29/05/2008 | n/a        |                        |                                                                                                                                                                                                                                                                     |
| N/0018  | Minorchangeinlabellingorpackageleafletnot connected with the SPC (Art.61.3 Notification)                                                              | 23/05/2008 | n/a        | PL                     |                                                                                                                                                                                                                                                                     |
| IA/0023 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                               | 06/05/2008 | 06/05/2008 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                     |
| IA/0022 | IA_41_a_01_Change in pack size -change in no.of units within range of appr. pack size                                                                 | 06/05/2008 | 06/05/2008 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                     |
| IA/0021 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                               | 06/05/2008 | 06/05/2008 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                     |
| IB/0017 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                            | 10/12/2007 | n/a        | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                     |
| IA/0016 | IA_07_a_Replacement/add.ofmanufacturingsite: Secondary packaging site IA_07_b_01_Replacement/add.ofmanufacturing site:Primarypackagingsite-Solidforms | 19/09/2007 | n/a        |                        |                                                                                                                                                                                                                                                                     |
| IA/0015 | IA_41_a_01_Change in pack size -change in no. of                                                                                                      | 13/09/2007 | 13/09/2007 | SmPC,                  |                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         | units within range of appr.pack size                                                    |            |            | Labelling and PL       |         |
|---------|-----------------------------------------------------------------------------------------|------------|------------|------------------------|---------|
| IA/0014 | IA_41_a_01_Change in pack size - change in no. of units within range of appr.pack size  | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
| IA/0013 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
| IA/0012 | IA_41_a_01_Change in pack size -change in no.of units withinrange of appr.pack size     | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
| IA/0011 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
| IA/0010 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
| IA/0009 | IA_41_a_01_Change inpack size-change in no.of units within range of appr. pack size     | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
| IA/0008 | IA_41_a_01_Change in pack size - change in no. of units within range of appr.pack size  | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
|         | IA_41_a_01_Change inpack size -change in no. of units within range of appr.pack size    | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL | IA/0007 |
|         | IB_14_b_Changeinmanuf.ofactivesubstance                                                 | 13/07/2007 | n/a        |                        | IB/0006 |

<div style=\"page-break-after: always\"></div>

|         | without Ph.Eur.certificate-new manufacturer                                      |            |     |                                  |
|---------|----------------------------------------------------------------------------------|------------|-----|----------------------------------|
| IA/0004 | IA_15_a_Submission ofPh.Eur.certificate for active                               | 27/04/2007 | n/a | substance- approved manufacturer |
| IA/0003 | IA_11_a_Change in batch size of active substance or                              | 02/04/2007 | n/a | intermediate - up to 10-fold     |
| IA/0002 | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold | 02/04/2007 | n/a |                                  |
| IA/0001 | IA_11_a_Change in batch size of active substance or                              | 02/04/2007 | n/a | intermediate-up to10-fold        |